First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
14 mars 2024 06h00 HE
|
First Wave BioPharma, Inc.
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave...
First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference
05 mars 2024 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
STATE OF CELIAC DISEASE IN CANADA - UNDERDIAGNOSED, UNAFFORDABLE AND UNSAFE FOOD: SURVEY
28 févr. 2024 11h09 HE
|
Celiac Canada
TORONTO, ON., Feb. 28, 2024 (GLOBE NEWSWIRE) -- February 28th, Toronto. Twenty years after the first comprehensive survey of Canadians living with celiac disease, new results show the condition...
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
13 févr. 2024 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Canada’s first gluten-free food service training guide improves patient health & saves lives.
23 janv. 2024 12h32 HE
|
Celiac Canada
TORONTO, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Celiac patients in hospitals and long-term care residents who cannot advocate for themselves are often served food containing gluten, which can lead to...
First Wave BioPharma to Present at the DealFlow MicroCap Conference
23 janv. 2024 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
17 janv. 2024 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
05 janv. 2024 16h01 HE
|
Barinthus Biotherapeutics
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
04 janv. 2024 06h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
27 déc. 2023 06h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...